Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. - Wikidata - awgldk - TriplyDB

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

http://www.wikidata.org/entity/Q50736531

about

Plasmodium Infection Is Associated with Impaired Hepatic Dimethylarginine Dimethylaminohydrolase Activity and Disruption of Nitric Oxide Synthase Inhibitor/Substrate Homeostasis Packed red blood cells are an abundant and proximate potential source of nitric oxide synthase inhibition Haemodialysis acutely reduces the plasma levels of ADMA without reversing impaired NO-dependent vasodilation.The relationship between hemoglobin levels and endothelial functions in diabetes mellitus Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review Nitric oxide synthetic pathway in red blood cells is impaired in coronary artery disease.Established and theoretical factors to consider in assessing the red cell storage lesion Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis.Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.The red blood cell: a new key player in cardiovascular homoeostasis? Focus on the nitric oxide pathway.Determination of Methylarginines in Infant Plasma by CE-LIF AltitudeOmics: Red Blood Cell Metabolic Adaptation to High Altitude Hypoxia Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine.Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease.Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption.Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors.Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity.Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia.

P2860

Q27317763-6B6C38BB-B1E9-479D-8E9F-91C5675CFD1D Q28544807-435322A3-17DB-48AB-973E-19498768664E Q33414818-0242CF8D-1D9F-4F0F-B3C3-ED1B038FB521 Q33571310-C74E5FA3-1E4A-4BFF-B238-F694D64EAD25 Q33646665-3A81D79B-5958-403F-AF93-CE9FA54A5C0E Q34934327-8ED4B400-5688-4703-8EE6-AD3EA21B941C Q35252618-02BE8ECA-5BCD-459A-A0ED-CC006CB7070B Q36083890-8890836B-9A9A-4BE8-B711-AF064F45C0AF Q37324434-8EED2DA2-3C80-4553-B590-645833FF76A9 Q38238643-F85C5C03-BB39-4384-B734-05DA04AA82B7 Q41527187-54EE8926-8B3F-486B-9D8D-686E24143A09 Q42380761-DDB6B0BE-9E89-47D4-80E5-0937E41E38B3 Q42502690-B24B69D4-B1F6-4AA3-BEAD-BAC3C5318D17 Q42769487-EB32C931-727F-4E59-8093-F40101F99D1D Q43074669-76ED46E5-AF9A-4C8E-B643-FB412B4D911D Q43590526-94919431-3AC6-4CF2-8898-1F1074E2A95C Q46609458-0972D6B4-16A4-40F7-A4E7-91ECA82F60B6 Q50951302-07C4C5D8-8C81-4313-999D-20258A907AA0

P2860

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

http://www.wikidata.org/entity/Q50736531

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@en

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@nl

type

label

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@en

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@nl

prefLabel

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@en

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@nl

P1433

Q50736531-D0EF21CA-5FAB-4097-9F74-634062DCBEBE

P1476

Q50736531-76370D7B-993E-48D0-9A7A-CB30DA25F83D

P2093

Q50736531-19FDF84B-44C1-41AF-8BCB-22A8311F9835

Q50736531-39232D8B-2598-4E5D-B239-0FF0D9701C5F

Q50736531-A60D6F0B-0659-4D3B-9244-5FC11A5068FD

Q50736531-AF224298-A075-42F6-B477-C76BE596A10B

Q50736531-B054DA01-7C2F-4EFF-AC64-20FF46D11E6F

Q50736531-E2A0EFD1-39C4-4E20-9ECB-81CAD309F821

Q50736531-E8E197D8-55B4-4931-8425-9C9EBCCEB281

P2860

Q50736531-023E293D-2359-4E26-8919-E790057C4E3B

Q50736531-028253EB-D7D0-4EA7-BFBB-3B29A793A88B

Q50736531-042D5427-BE7C-4D97-95B6-5C2CF21F76F3

Q50736531-05097090-914C-417D-B209-4F72F07BC15E

Q50736531-07501FE0-34F4-4543-9FB1-46C2CC6E6B54

Q50736531-0CF6A97D-971F-49BC-AE9E-C1CFAFE03143

Q50736531-1AA168C1-4C36-4D4D-831E-57835E1A8764

Q50736531-1D8B84DA-9E70-42A1-8AE3-439676C3D3D6

Q50736531-1FB64372-0AE4-43EC-9653-EE1F96DB3347

Q50736531-234D8589-CA68-4023-9EDD-5CCE1B3ABB84

P304

Q50736531-3DDA267D-9DC2-4003-B805-C56ADEBAA81A

P31

Q50736531-277E41B6-949D-46AA-BC89-88392F99A18F

P356

Q50736531-E6C8633D-5D16-4B7D-837E-C7D9459FC3C2

P433

Q50736531-5CA44558-7F8B-4485-B71A-E76F499931EC

P478

Q50736531-9C2D4D00-4F21-424E-9736-1D33CE27FFAC

P577

Q50736531-89878C39-8ED8-459C-8FED-277E29A0299D

P5875

Q50736531-B5256439-21F5-461D-BFEB-EAEAB97B1F51

P698

Q50736531-AFCF8460-C8B9-4F97-848B-01F865A0AD08

P356

AJPHEART.00066.2006

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.

@en

P2093

Alia V Hinz

http://www.w3.org/2001/XMLSchema#string

Joseph J Northrup

http://www.w3.org/2001/XMLSchema#string

Laura A Kitzmiller

http://www.w3.org/2001/XMLSchema#string

Louis G D'Alecy

http://www.w3.org/2001/XMLSchema#string

Masumi Kimoto

http://www.w3.org/2001/XMLSchema#string

Scott S Billecke

http://www.w3.org/2001/XMLSchema#string

Steven E Whitesall

http://www.w3.org/2001/XMLSchema#string

P2860

FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1

PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation

S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase

Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

Decrease of 3-methylhistidine and increase of NG,NG-dimethylarginine in the urine of patients with muscular dystrophy

Dimethylarginines in chronic renal failure

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn(II) release activates DDAH-1.

Does ADMA cause endothelial dysfunction?

P304

H1788-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00066.2006

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7147357

http://www.w3.org/2001/XMLSchema#string

P698

16632550

http://www.w3.org/2001/XMLSchema#string